Postprandial hypertriglyceridemia occurs when the rapid absorption of dietary fat (in the form of chylomicron triglycerides) overwhelms the body's ability to clear plasma triglyceride. In its most severe form, postprandial hypertriglyceridemia can lead to chylomicronemia and a greatly increased risk of acute, life-threatening pancreatitis. Joining host Dr. Alan Brown to talk about this condition and a trial drug treatment in research and development is Dr. Dan Meyers, one of the top winners in the Abstracts Program of the National Lipid Association's Annual Scientific Sessions. Dr. Meyers is currently a Translational Medicine Expert with Novartis Institutes of Biomedical Research (NIBR) in Cambridge, MA. While at NIBR, he has designed and executed first-in-human, proof of concept, and mechanistic studies with novel compounds intended for the treatment of dyslipidemia, diabetes and related metabolic disease.